Recent Advances in Asymmetric Synthesis of 1,4‐Dihydropyridines

The 1,4-dihydropyridine (1,4-DHP) scaffold is a privileged scaffold in numerous therapeutic agents, including L-type calcium channel blockers, mineralocorticoid receptor antagonists, and calcitonin gene-related peptide receptor antagonists. The chirality at the C4 position of the 1,4-DHP core critically influences its pharmacological activity. Recent advances in asymmetric synthesis, particularly through organocatalysis and transition metal catalysis, have enabled efficient and stereoselective routes to access enantiomerically enriched 1,4-DHP derivatives. However, a comprehensive review summarizing these asymmetric synthetic strategies for this pivotal scaffold is still lacking. This article systematically summarizes recent progress in the asymmetric synthesis of 1,4-DHPs, focusing on catalytic systems involving organocatalysts and transition metal complexes. It further highlights their significant potential in constructing key chiral intermediates for pharmaceutical development, aiming to provide novel perspectives for the research and development of chiral 1,4-DHP-based drugs.

Authors

Institutions

Publication Details

Journal
ChemBioChem
Published
2026-04-14
DOI
https://doi.org/10.1002/cbic.202500894
Primary Topic
Asymmetric Synthesis and Catalysis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Recent Advances in Asymmetric Synthesis of 1,4‐Dihydropyridines

Kuo Ren, Jie Feng, Hongchao Shi, Junmian Yang et al.
ChemBioChem
Asymmetric Synthesis and Catalysis
article

Recent Advances in Asymmetric Synthesis of 1,4‐Dihydropyridines

Kuo Ren, Jie Feng, Hongchao Shi, Junmian Yang, Yifeng Huang, Yuxuan Yan, Yongbin Cui, Yongqing Ma
article en

Abstract

The 1,4-dihydropyridine (1,4-DHP) scaffold is a privileged scaffold in numerous therapeutic agents, including L-type calcium channel blockers, mineralocorticoid receptor antagonists, and calcitonin gene-related peptide receptor antagonists. The chirality at the C4 position of the 1,4-DHP core critically influences its pharmacological activity. Recent advances in asymmetric synthesis, particularly through organocatalysis and transition metal catalysis, have enabled efficient and stereoselective routes to access enantiomerically enriched 1,4-DHP derivatives. However, a comprehensive review summarizing these asymmetric synthetic strategies for this pivotal scaffold is still lacking. This article systematically summarizes recent progress in the asymmetric synthesis of 1,4-DHPs, focusing on catalytic systems involving organocatalysts and transition metal complexes. It further highlights their significant potential in constructing key chiral intermediates for pharmaceutical development, aiming to provide novel perspectives for the research and development of chiral 1,4-DHP-based drugs.

ChemBioChemVol. 27(7)
Shenyang Pharmaceutical University (CN), China Pharmaceutical University (CN), Buchang Pharma (China) (CN), Shijiazhuang Yiling Pharmaceutical (China) (CN)
Openalex Percentile: Top 15%
Asymmetric Synthesis and Catalysis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Recent Advances in Asymmetric Synthesis of 1,4‐Dihydropyridines — Kuo Ren, Jie Feng, et al. · ChemBioChem (2026) | TGRS Research Map | TGRS